Format

Send to

Choose Destination
Epigenomics. 2015;7(6):881-3. doi: 10.2217/epi.15.61. Epub 2015 Sep 29.

Interview with Stephen B Baylin.

Author information

1
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA.

Abstract

Stephen B Baylin is a codirector of the Cancer Biology Program at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Virginia and DK Ludwig Professor of Oncology and Medicine. Baylin attended Duke University, where he earned his medical degree and completed his internship and first year residency in internal medicine. He then worked for 2 years at the National Heart and Lung Institute of the NIH. In 1971, he joined the departments of oncology and medicine at Johns Hopkins University School of Medicine. His research interests include cellular biology and genetics of cancer, specifically epigenetics or genetic modifications other than those in DNA that can affect cell behavior, and silencing of tumor suppressor genes and tumor progression. His research has looked at the mechanisms through which variations in tumor cells derive, and cell differentiation in cancers such as medullary thyroid carcinoma and small-cell lung carcinoma. He has served on the American Association for Cancer Research Board of Directors, and is an associate editor of Cancer Research. He has also presented frequently at AACR conferences and chaired the special conference on 'DNA Methylation, Imprinting and the Epigenetics of Cancer'. He has authored or coauthored more than 370 publications.

PMID:
26418030
DOI:
10.2217/epi.15.61
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center